Insight Molecular Diagnostics
IMDX
26 hedge funds and large institutions have $11.4M invested in Insight Molecular Diagnostics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.11% more ownership
Funds ownership: 55.25% → 55.37% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 30 → 26 (-4)
20% less capital invested
Capital invested by funds: $14.3M → $11.4M (-$2.92M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$327K |
| 2 |
AIC
AWM Investment Company
New York
|
+$108K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.38K |
| 5 |
Renaissance Technologies
New York
|
+$1.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$219K |
| 2 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$132K |
| 3 |
Millennium Management
New York
|
-$48.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$363 |
IMDX Hedge Fund Activity: Q4 2023 in Review
26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2023, worth a combined $11.4M — down 20% from $14.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMDX and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $327K. The largest seller was Pura Vida Investments, cutting an estimated $219K.
- 26 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2023, down from 30 in Q3 2023.
- Funds reported $11.4M of Insight Molecular Diagnostics stock for Q4 2023, down 20% quarter-over-quarter.
- 1 fund opened new Insight Molecular Diagnostics positions in Q4 2023 and 5 closed out, a net change of -4 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2023 was Morgan Stanley, an estimated $327K added.
- The largest Insight Molecular Diagnostics seller in Q4 2023 was Pura Vida Investments, an estimated $219K sold.
Based on aggregated 13F filings for Q4 2023.